Effect of Astilbin on Experimental Diabetic Nephropathy in vivo and in vitro

Abstract

Astilbin, a flavonoid compound, was isolated from the rhizome of Smilax glabra Roxb. This study was conducted to investigate the efficacy of astilbin on experimental diabetic nephropathy (DN) in vivo and in vitro and its possible mechanisms. Astilbin was added in high glucose stimulated HK-2 cells, streptozotocin-induced experimental DN, randomized to receive intragastric (i. g.) astilbin to observe its anti-renal lesion effect. Results showed that astilbin inhibited high glucose stimulated HK-2 cell production of transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) in vitro, especially CTGF; analogic results was also found in vivo. I. g. of astilbin 2.5 mg/kg or 5 mg/kg significantly ameliorated renal function, reduced kidney index, while it increased body weight and survival time in animals. In addition there was no significant difference in blood glucose level between the STZ-treated group and the astilbin groups. Furthermore, astilbin ameliorated the pathological progress of renal morphology. Astilbin can exert an early renal protective role to DN, inhibit production of TGF-β1 and especially of CTGF. We suggest that astilbin inhibition of CTGF may be a potential target in DN therapy. This work provides the first evidence for astilbin as a new candidate of DN therapeutic medicine.

Key words

astilbin (3‐0‐alpha‐1‐rhamnosyl‐(2R,3R)‐dihydroquercetin) - transforming growth factor‐β1 - connective tissue growth factor - diabetic nephropathy

References

• 1 Ziyadeh F N, Sharma K. Overview: combating diabetic nephropathy.  J Am Soc Nephrol. 2003;  14 1355-1357
• 2 Abdel W N, Mason R M. Connective tissue growth factor and renal diseases: some answers, more questions.  Curr Opin Nephrol Hypertens. 2004;  13 53-58
• 3 Van Nieuwenhoven F A, Jensen L J, Flyvbjerg A, Goldschmeding R. Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point?.  Nephrol Dial Transplant. 2005;  20 6-10
• 4 Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway.  Am J Pathol. 2004;  165 2033-2043
• 5 Kobayashi T, Okada H, Inoue T, Kanno Y, Suzuki H. Tubular expression of connective tissue growth factor correlates with interstitial fibrosis in type 2 diabetic nephropathy.  Nephrol Dial Transplant. 2006;  21 548-549
• 6 Goldschmeding R, Aten J, Ito Y, Blom I, Rabelink T, Weening J J. Connective tissue growth factor: just another factor in renal fibrosis?.  Nephrol Dial Transplant. 2000;  15 296-299
• 7 Boor P, Sebeková K, Ostendorf T, Floege J. Treatment targets in renal fibrosis.  Nephrol Dial Transplant. 2007;  22 3391-3407
• 8 Haraguchi H, Mochida Y, Sakai S, Masuda H, Tamura Y, Mizutani K, Tanaka O, Chou W H. Protection against oxidative damage by dihydroflavonols in Engelhardtia chrysolepis.  Biosci Biotechnol Biochem. 1996;  60 945-948
• 9 Igarashi K, Uchida Y, Murakami N, Mizutani K, Masuda H. Effect of astilbin in tea processed from leaves of Engelhardtia chrysolepis on the serum and liver lipid concentrations and on the erythrocyte and liver antioxidative enzyme activities of rats.  Biosci Biotechnol Biochem. 1996;  60 513-515
• 10 Wang J, Zhao Y, Xu Q. Astilbin prevents concanavalin A-induced liver injury by reducing TNF-α production and T lymphocytes adhesion.  J Pharm Pharmacol. 2004;  56 495-502
• 11 Xu Q, Wu F, Cao J, Chen T, Jiang J, Saiki I, Koda A. Astilbin selectively induces dysfunction of liver-infiltrating cells: novel protection from liver damage.  Eur J Pharmacol. 1999;  377 93-100
• 12 Yan R, Xu Q. Astilbin selectively facilitates the apoptosis of interleukin-2-dependent phytohemagglutinin-activated Jurkat cells.  Pharmacol Res. 2001;  44 135-139
• 13 Cai Y, Chen T, Xu Q. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes.  Inflamm Res. 2003;  52 334-340
• 14 Fei M J, Wu X F, Xu Q. Astilbin inhibits contact hypersensitivity via negative cytokine regulation distinct form cyclosporin A.  J Allergy Clin Immunol. 2005;  116 1350-1356
• 15 Chen T, Li J, Cao J, Xu Q, Komatsu K, Namba T. A new flavanone isolated from Rhizoma Smilacis glabrae and the structural requirements of its derivatives for preventing immunological hepatocyte damage.  Planta Med. 1999;  65 559-563
• 16 Panchapakesan U, Sumual S, Pollock C A, Chen X. PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose.  Am J Physiol Renal Physiol. 2005;  289 1153-1158
• 17 Thulesen J, Poulsen S S, Jørgensen P E, Nexø E. Adrenergic blockade in diabetic and uninephrectomized rats: effects on renal size and on renal and urinary contents of epidermal growth factor.  Nephron. 1999;  81 172-182
• 18 Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies.  N Engl J Med. 1998;  339 1448-1456
• 19 Mauer S M. Structural-functional correlations of DN.  Kidney Int. 1994;  45 612-622
• 20 Wolf G, Ziyadeh F N. Molecular mechanisms of diabetic renal hypertrophy.  Kidney Int. 1999;  56 393-405
• 21 Paueksakon P, Revelo M P, Ma L J, Marcantoni C, Fogo A B. Microangiopathic injury and augmented PAI‐1 in human diabetic nephropathy.  Kidney Int. 2002;  61 2142-2148
• 22 Lee H B, Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy.  Nephrology. 2005;  10 S11-S13
• 23 Bottinger E P, Letterio J J, Roberts A B. Biology of TGF-β1 in knockout and transgenic mouse models.  Kidney Int. 1997;  51 1355-1360
• 24 Schull M M, Ormsby I, Kier A B. Targeted disruption of the mouse TGF-β1 gene results in multifocal inflammatory disease.  Nature. 1992;  359 693-699
• 25 Rossing P. Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus.  Diabet Med. 1998;  15 900-919
• 26 Lewis E J, Hunsicker L G, Bain R P, Rohde R D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.  N Engl J Med. 1993;  329 1456-1462

1 These authors contributed equally to this project and should be considered co-first authors.